Evidence map›Paper›PMID 40815315›Full record

ArticleArchives of toxicology2025

Polychlorinated biphenyls (PCBs) interact with drug metabolism in vivo.

Julian Peter Müller, Jens Rengelshausen, Salah Laieb, Maryam Safavi, Andrea Kaifie, Andre Esser, Thomas Schettgen, Jens Bertram, Julia Krabbe, Elke Schaeffeler and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Julian Peter Müller *Institute of Clinical Pharmacology, University Hospital of RWTH, 52074, Aachen, Germany.
Jens Rengelshausen *Institute for Occupational, Social and Environmental Medicine, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Salah Laieb *Institute for Occupational, Social and Environmental Medicine, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Maryam SafaviInstitute for Occupational, Social and Environmental Medicine, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Andrea KaifieInstitute for Occupational, Social and Environmental Medicine, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Andre EsserInstitute for Occupational, Social and Environmental Medicine, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Thomas SchettgenInstitute for Occupational, Social and Environmental Medicine, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Jens BertramInstitute for Occupational, Social and Environmental Medicine, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Julia KrabbeInstitute for Occupational, Social and Environmental Medicine, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Elke SchaeffelerDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Tuebingen, Germany.
Jens SarömbaInstitute of Clinical Pharmacology, University Hospital of RWTH, 52074, Aachen, Germany.
Katja S JustInstitute of Clinical Pharmacology, University Hospital of RWTH, 52074, Aachen, Germany.
Roman TremmelDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Tuebingen, Germany.
Matthias SchwabDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Tuebingen, Germany.
Julia C StinglInstitute of Clinical Pharmacology, University Hospital of RWTH, 52074, Aachen, Germany.
Thomas KrausInstitute for Occupational, Social and Environmental Medicine, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Patrick ZieglerInstitute for Occupational, Social and Environmental Medicine, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany. pziegler@ukaachen.de.ORCID 0000-0003-4017-8244

Funding

Deutsche Forschungsgemeinschaft 455749974Deutsche Forschungsgemeinschaft 502906636
6 · The paper itself

Abstract

Polychlorinated biphenyls (PCBs) are widespread environmental contaminants that interfere with xenobiotic metabolism, primarily by modulating cytochrome P450 (CYP) enzymes. However, their pharmacokinetic consequences in exposed individuals remain poorly defined. Here, we investigated the impact of PCB exposure on CYP enzyme activity using a combined clinical pharmacokinetic and in vitro mechanistic approach. Ten occupationally PCB-exposed individuals from the German HELPcB cohort and ten controls received a CYP phenotyping cocktail to assess enzyme function (Clinical Trial Registry: DRKS00028922). Plasma drug and metabolite concentrations were quantified to evaluate CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A activity, considering genetically defined metabolizer status. PCB118 exposure was significantly associated with reduced CYP1A2 activity (R

Indexed as

Cytochrome P-450 Enzyme SystemEnvironmental PollutantsOccupational ExposurePolychlorinated BiphenylsAdultFemaleHumansMaleMiddle AgedCytochrome P-450 Enzyme SystemEnvironmental PollutantsPolychlorinated BiphenylsCYP1A2/CYP2C9 enzyme modulationCytochrome P450Drug metabolismEnvironmental toxicologyPolychlorinated biphenyls (PCBs)

Identifiers

PMID40815315
PMCPMC12477080

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.